Description: In this webcast, presenters will outline the key content in ERM ASOPs 46, 47 and 55 and explore the impact each ASOP has on practitioners working in these fields. We will also describe the revision work currently under way in the ERM Committee of the Actuarial Standards Board.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Discover the rapidly developing health and wellness industry during the Use of Health and Wellness Data in L&H Risk Assessment webcast. Our discussion includes the maximization of data usage through several different means, including current risk selection, creation of a dynamic ongoing assessment offering or substitution of traditional underwriting information to shorten the underwriting process. Come explore these different approaches as they affect the health and wellness industry. We will express the importance of a constantly changing data usage environment in order to better prepare insurers to maximize their data and drive health and wellness forward.

Description: Learn from panelists from different companies as they come together to discuss their experiences.

Description: Gather with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, pension, investment, product strategy, and more.